継続的走運動および筋p62/Sqstm1は非アルコール性脂肪性肝炎の発症と進展を抑制する

1.

Younossi ZM. (2019). Non-alcoholic fatty liver disease - A global public health

perspective. J Hepatol 70 (3): 531-544.

2.

Loomba R., Friedman SL., Shulman GI. (2021). Mechanisms and disease

consequences of nonalcoholic fatty liver disease. Cell 184 (10): 2537-2564.

3.

Eguchi Y., Hyogo H., Ono M., Mizuta T., Ono N., Fujimoto K., et al. (2012).

Prevalence and associated metabolic factor of nonalcoholic fatty liver disease in the

general population from 2009 to 2010 in Japan: a multicenter large retrospective

study. J Gastroenterol 47(5): 586-95.

4.

Chalasani N., Younossi Z., Lavine JE., Charlton M., Cusi K., Rinella M., et al.

(2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice

guidance from the American Association for the study of Liver Diseases.

Hepatology 67 (1): 328-357.

5.

Estes C., Anstee QM., Arias-Loste MT., Bantel H., Bellentani S., Caballeria J., et al.

(2018). Modeling NAFLD disease burden in Chaina, France, Germany, Italy, Japan,

Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 69

(4): 896-904.

6.

Tateishi R., Uchino K., Fujiwara N., Takehara T., Okanoue T., Seike M., et al.,

(2019). A nationwide survey on non-B, non-C, hepatocellular carcinoma in Japan:

2011-2015 update. J Gastroenterol 54 (4): 367-376.

7.

Tilg H., Moschen AR. (2010). Evolution of inflammation in nonalcoholic fatty liver

disease: the multiple parallel hits hypothesis. Hepatology 52 (5): 1836-46.

8.

Bhanji R., Narayanan P., Allen AM., Malhi H., Watt KD. (2017). Sarcopenia in

hiding: The risk and consequence of underestimating muscle dysfunction in

nonalcoholic steatohepatitis. Hepatology 66 (6): 2055-2065.

9.

Wigg AJ., Roberts-Thomson IC., Dymock RB., McCarthy PJ., Grose RH.,

Cummins, AG. (2001). The role of small intestinal bacterial overgrowth intestinal

permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of

non-alcoholic steatohepatitis. Gut 48(2): 206-11.

62

10. Bouwens L., Baekeland M., De-Zanger R., Wisse E. (1986). Quantitation, tissue

distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology

6: 718-722.

11. Smedsrod B., De-Bleser PJ., Braet F., Lovisetti P., Vanderkerken K., Wisse W., et al.

(1994). Cell biology of liver endothelial and Kupffer cells. Gut 35 (11): 1509-16.

12. Shida T., Akiyama K., Oh S., Sawai A., Isobe T., Okamoto Y., et al. (2018). Skeletal

muscle mass to visceral fat area ratio is an important determinant affecting hepatic

conditions of non-alcoholic fatty liver disease. J Gastroenterol 53 (4): 535-547.

13. Komine S., Akiyama K., Warabi E., Oh S., Kuga K., Ishige K., et al. (2017).

Exercise training enhances in vivo clearance if endotoxin and attenuates

inflammatory response by potentiating Kupffer cell phagocytosis. Sci Rep 7 (1):

11977.

14. Oh S., Shida T., Yamagishi K., Tanaka K., So R., Tsujimoto T., et al. (2015).

Moderate to vigorous physical activity volume is an important factor for managing

nonalcoholic fatty liver disease: A Retrospective Study. Hepatology 61 (4): 12051215.

15. Oh S., Tsujimoto T., Kim B., Uchida F., Suzuki H., Iizumi S., et al. (2021). Weightloss-independent benefits of exercise on liver steatosis and stiffness in Japanese

men with NAFLD. JHEP Rep 3 (3): 100253.

16. Oh S., So R., Shida T., Matsuo T., Kim B., Akiyama K., et al. (2017). Highintensity aerobic exercise improves both hepatic fat content and stuffiness in

sedentary obese men with nonalcoholic fatty liver disease. Sci Rep 7: 43029.

17. Nachit M., Kwanten WJ., Thissen J., Beeck R., Gaal LV., Vonghia L., et al. (2021).

Muscle fat content is strongly associated with NASH: A longitudinal study in

patients with morbid obesity. J Hepatol 75 (2): 292-301.

18. Nachit M., Rudder MD., Thissen J., Schakman O., Bouzin C., Horsmans Y., et al.

(2020). Myosteatosis rather than sarcopenia associates with non-alcoholic

steatohepatitis in non-alcoholic fatty liver disease preclinical models. J Cachexia

Sarcopenia Muscle 12 (1): 144-158.

19. Santos J., Maio M., Lemes M., Laurindo L., Haber J., Bechara., et al. (2022). Non-

63

Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will

Be in the Future. Int J Mol Sci 23 (1): 498.

20. Argiles JM., Campos N., Lopez-Pedrosa JM., Rueda R., Rodriguez-Manas L.

Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Role in Health and

Disease. J Am Med Dir Assoc 2016; 17 (9): 789-96.

21. Hong S., Chang Y., Jung HS., Yun KE., Shin H., Ryu S. Relative muscle mass and

the risk of incident type 2 diabetes: A cohort study. PLos One 2017; 12 (11):

e0188650.

22. Oshida N., Shida T., Oh S., Kim T., Isobe T., Okamoto Y., et al. (2019). Urinary

Levels of Titin-N-Fragment, a Skeletal Muscle Damage Marker, are Increased in

Subjects with Nonalcoholic Fatty Liver Disease. Sci Rep 9 (1): 19498.

23. Bucci M., Huovinen V., Guzzardi MA., Koskinen S., Raiko JR., Lipponen H., et al.

(2016). Resistance training improves skeletal muscle insulin sensitivity in elderly

offspring of overweight and obese mothers. Diabetologia 59 (1): 77-86.

24. Zierath JR., Krook A., Henriksson W. (2000). Insulin action and insulin resistance in

human skeletal muscle. Diabetologia 43: 821-835.

25. Guo S. (2014). Insulin signaling, and the metabolic syndrome: insights from mouse

models into disease mechanisms. J Endocrinol 220 (2): 1-23.

26. Rommel C., Bodine SC., Clarke BA., Rossman R., Nunez L., Stitt TN., et al. (2001).

Mediation of IGF-1-induce skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and

PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3 (11): 1009-13.

27. Bodine SC., Stitt TN., Gonzalez M., Kline WO., Stover GL., Bauerlein R., et al.

(2001). Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and

can prevent muscle atrophy in vivo. Nat Cell Biol 3 (11): 1014-9.

28. Glass DJ. (2005). Skeletal muscle hypertrophy and atrophy signaling pathway. Int J

Biochem Cell Biol 37 (10): 1974-84.

29. Tanaka M., Masuda S., Yamakage H., Inoue T., Ohue-Kitano R., Yokota S., et al.

(2018). Role of serum myostatin in the association between hyperinsulinemia and

muscle atrophy in Japanese obese patients. Diabetes Res Clin Pract 142: 195-202.

64

30. Harada H., Warabi E., Matsuki T., Yanagawa T., Okada K., Uwayama J., et al. (2013).

Deficiency of p62/sequestosome 1 causes hyperphagia due to leptin resistance in the

brain. J Neurosci 33 (37): 1467-77.

31. Okada K., Yanagawa T., Warabi E., Yamastu K., Uwayama J., Takeda K., et al. (2009).

The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in

sequestosome 1/A170/p62 deficient mice. Hepatol Res 39 (5): 490-500.

32. Duran A., Hernandez ED., Reina-Campos M., Casrilla EA., Sunbramaniam S.,

Raghunandan S., et al. (2016). p62/SQSTM1 by binding to vitamin D Receptor

Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer. Cancer Cell 30

(4): 595-609.

33. Imajo K., Yoneda M., Kessoku T., Ogawa Y., Maeda S., Sumida Y., et al. (2013).

Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int J

Mol Sci 14 (11): 21833-57.

34. Rinella ME., Elias MS., Smolak RR., Fu Tao., Borensztajn J., Green RM. (2008).

Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient

diet. J Lipid Res 49 (5): 1068-76.

35. Sakuma K., Kinoshita M., Ito Y., Aizawa M., Aoi W., Yamaguchi A. p62/SQSTM1

but not LC3 is accumulated in sarcopenia muscle of mice. (2016). J Cachexia

Sarcopenia Muscle 7 (2): 204-12.

36. Sauer B. (1987). Functional expression of the cre-lox site-specific recombination

system in the yeast Saccharomyces cerevisiae. Mol Cell Biol 7 (6): 2087-96.

37. Akiyama K., Warabi E., Okada K., Yanagawa T., Ishii T., Kose K., et al. (2018).

Deletion of both p62 and Nrf2 spontaneously results in development of nonalcoholic

steatohepatitis. Exp Anim 67 (2): 201-218.

38. Bedossa P., Poitou C., Veyrie N., Bouillot JL., Basdevant A., Paradis V., et al. (2012).

Histopathological algorithm and scoring system for evaluation of liver lesions in

morbidly obese patients. Hepatology 56 (5): 1751-9.

39. Schefer V., & Talan M., (1996). Oxygen consumption in adult and AGED C57BL/6J

mice during acute treadmill exercise of different intensity. Exp Gerontol 31: 387-392.

65

40. Yano H., Kinoshita S., & Kira S. (2004). Effects of acute moderate exercise on the

phagocytosis of Kupffer cells in rat. Acta Physiologica Scandinavica 182: 151-160.

41. Kinoshita K., Uchida T., Sato A., Nakashima M., Nakashima H., Shono S., et al.

(2010). Characterization of two F4/80-postive Kupffer cell subsets by their function

and phenotype in mice. J Hepatol 53 (5): 903-910.

42. Ben-Nathan D., Padgett DA., & Loria RM. (1999). Androstenediol and

dehydroepiandrosterone protect mice against lethal bacterial infections and

lipopolysaccharide toxicity. J Med Microbiol 48 (5): 425-431.

43. Loomba R., & Chalasani N. (2015). The Hierarchical Model of NAFLD: Prognostic

significance of histologic features in NASH. Gastroenterology 149 (2): 278- 281.

44. Gehrke N., Biedenbach J., Huber Y., Straub B., Galle PR., Simon P., et al. (2019).

Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune

phenotype and improves metabolic parameters - an animal model of lifestyle

intervention in NAFLD. Sci Rep 9 (1): 4007.

45. Kawanishi N., Yano H., Mizokami T., Takahashi M., Oyanagi E., & Suzuki K. (2012).

Exercise training attenuates hepatic inflammation, fibrosis, and macrophage

infiltration during diet induced obesity in mice. Brain, Behav Immun 26 (6): 931-41.

46. Bongiovanni B., Mata-Espinosa D., D' Attilio L., Leon-Contreras JC., MarquezVelasco R., Bottasso O., et al. (2015). Effect of cortisol and/or DHEA on THP1derived macrophages infected with Mycobacterium tuberculosis. Tuberculosis

(Edinb) 95 (5): 562-569.

47. Cao J., Yu L., Zhao J., & Ma H. (2019). Effect of dehydroepiandrosterone on the

immune function of mice in vivo and in vitro. Molecular Immunology 112: 283-290.

48. Rabe T., Ahrendt H J., Albring C., Bachmann A., Bitzer J B P U., Egarter C., et al.

(2015). Dehydroepiandrosterone and its sulfate joint statement by the German

Society for Gynecological Endocrinology and Reproductive Medicine (DGGEF) and

the German Professional Association of Gynecologist (BVF). J Reproduktionsmed

Endokrinol 12: 318–341.

49. Tatara K., & Sato L. (2019). Aerobic exercise training and dehydroepiandrosterone

administration increase testicular sex steroid hormones and enhance reproductive

66

function in high-sucrose-induced obese rats. J Steroid Biochem Mol Biol 190: 37-43.

50. Danenberg HD., Alpert G., Lusting S., & Ben-Nathan D. (1992).

Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor

necrosis factor production. Antimicrob Agents Chemother 36 (10): 2275-2279.

51. Kahn SE., Hull RL., Utzschneider KM. (2006). Mechanisms linking obesity to

insulin resistance and type 2 diabetes. nature 444 (7121): 840-6.

52. Shoelson SE., Lee J., Goldfine AB. (2006). Inflammation and insulin resistance. J

Clin Invest 116 (7): 1793-801.

53. Kodama S., Horikawa C., Fujihara K., Yoshizawa S., Yachi Y., Tanaka S., et al.

(2014). Quantitative relationship between body weight gain in adulthood and

incident type 2 diabetes: a meta-analysis. Obes Rev 15 (3): 202-14.

54. Duran A., Amanchy R., Linares JF., Joshi J., Abu-Baker S., Porollo A., et al. (2011).

p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol Cell 44 (1):

134-146.

55. Katsuragi Y., Ichimura Y., Komatsu M. (2015). p62/SQSTM1 functions as a signaling

hub and an autophagy adaptor. FEBS J 282 (24): 4672-8.

56. Newman AB., Kupelian V., Visser M., Simonsick E., Bret G., Nevitt M., et al. (2003).

Sarcopenia: alternative definitions and associations with lower extremity function. J

Am Geriatr Soc 51 (11): 1602-9.

57. Muller TD., Lee SJ., Jastroch M., Kabra D., Stemmer K., Aicheler M., et al. (2013).

p62 links β-adrenergic input to mitochondrial function and thermogenesis. J Clin

Invest 123 (1): 469-78.

58. He L., Antonucci L., Yamachika S., Zhang Z., Taniguchi K., Umemura A., et al.

(2020). NRF2 activates growth factor genes and downstream AKT signaling to

induce mouse and human hepatomegaly. J Hepatol 72 (6): 1182-1195.

59. Yoon MS. (2017). mTOR as a key Regulator in Maintaining Skeletal Muscle Mass.

Front Physiol 8: 788.

60. Sugiyama M., Yoshizumi T., Yoshida Y., Bekki Yuki., Matsumoto Y., Yoshiya S., et

al. (2017). p62 Promotes Amino Acid Sensitivity of mTOR Pathway and Hepatic

67

Differentiation in Adult Liver Stem/Progenitor Cells. J Cell Physiol 232 (8): 21122124.

61. Sugimoto R., Enjoji M., Kohjima M., Tsuruta S., Fukushima M., Iwao M., et al.

(2005). High glucose stimulates hepatic stellate cells to proliferate and to produce

collagen through free radical production and activation of mitogen-activated protein

kinase. Liver Int 25 (5): 1018-26.

62. Svegliati-Baroni G., Ridolfi F., Di Sario A., Casini A., Marucci L., Gaggiotti G., et

al. (1999). Insulin and insulin-like growth factor-1 stimulate proliferation and type

Ⅰ collagen accumulation by human hepatic stellate cells: differential effects on signal

transduction pathways. Hepatology 29 (6): 1743-51.

63. Charlton M., Angulo P., Chalasani N., Merriman R., Viker K.,

Charatcharoenwitthaya P., et al. (2008). Low circulating levels of

dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.

Hepatology 47 (2): 484-92.

64. Yamada M., Iwata M., Warabi E., Oishi H., Lisa V A., Okutsu M. (2019).

p62/SQSTM1 and Nrf2 are essential for exercise-mediated enhancement of

antioxidant protein expression in oxidative muscle. FASEB J 33 (7): 8022-8032.

（参考文献）

和田聖大．(2020)．継続的走運動は高脂肪食摂

p62 欠損マウスにおける肝の

炎症および線維化を抑制する．修士論文．

68

...